Sanzyme Biologics Received NSF certification for GENOME VALLEY Plant

Sanzyme Biologics Pvt. Ltd is now registered with The NSF Dietary Supplement Certification Program which has assessed and confirmed compliance of its facility situated at Genome Valley, Hyderabad (Telangana).  With the NSF certification, the company is now FSMA and cGMP compliant for their partners.

“NSF International, is a US certification body, whose mark on our facility is an assurance for our customers that our product has been tested by one of the most respected independent certification organization in existence today. Sanzyme Biologics is already a recognized name in the Indian biotechnology industry for the past 50 years and works with reputed companies in over 30 countries, this certification will give us an edge to widen our global footprint” said Dhruv Soman, Executive Director of Sanzyme Biologics.

Sanzyme Biologics is a 50 year old biotechnology company based in Hyderabad, India. Sanzyme specialises in the production of probiotic bacteria. Sanzyme’s best studied probiotic product is Bacillus coagulans SNZ 1969™. SNZ 1969 is a well-studied and documented strain with 20+ Clinical Trials and multiple regulatory approvals (FDA GRAS, Infant GRAS, EFSA QPS, Health Canada, FSSAI and others). It is currently sold in and used in 30+ countries including USA, Italy, Canada, Australia and Japan.

NSF Listing of Sanzyme Biologics: Read More

Introduction to Sanzyme’s Bacillus Subtilis SNZ 1972

Bacillus subtilis is a rod shaped, probiotic bacterium. It is found in the soil like most members of the Bacillus family and the gastrointestinal tract of ruminants and humans. Bacillus subtilis bacteria secrete commercially important industrial enzymes such as amylase, protease,pullulanase, chitinase, xylanase, lipase, among others. Bacillus subtilis is also responsible for producing antibiotics like bacitracin (effective against Gram-positive bacteria), polymyxin (affective against Gram-negative bacteria), difficidin (a broader spectrum), subtilin, and mycobacillin.

Bacillus subtilis SNZ 1972 was originally isolated from the soil by Sanzyme Biologics after extensive screening and characterization of various strains of Bacillus subtilis. By virtue of ability to form stress-resistant shield (endospore) Bacillus subtilis SNZ 1972 can protect itself against many stress situations such as acidic, alkaline, osmotic, or oxidative conditions, and heat. It survives through all manufacturing processes and it does not show decrement in viability of cell.

Safety of Bacillus subtilis SNZ 1972 is verified by a series of in vitro and in vivo studies. Based on these scientific procedures, Bacillus subtilis SNZ 1972 spores received self-affirmed GRAS (generally recognized as safe) status and it is intended for use as a food ingredient for consumers in the following food categories: bakery, cereal bars, dairy products and vegetable and fruit juices. Bacillus subtilis SNZ 1972 has also been studied for healthy digestion

 

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Introduction to Sanzyme’s Bacillus Coagulans SNZ 1969

History

Bacillus coagulans is a spore forming, probiotic strain. In 1949, Dr.Oki Nakayama from the University of Yamanashi in Japan isolated a species of spore forming lactic acid bacteria from green malt. It was deposited in the ATCC by Japanese researchers and later reclassified as Bacillus coagulans. In 1972, at the request of Sankyo Corporation, the Japanese Ministry of Health and Welfare approved the use of a B. coagulans strain (designated as strain SANK 70258).Subsequently, in 1973, Sankyo Corporation (currently known as Daiichi Sankyo Co. Ltd) offered formulation and fermentation technology to Sanzyme Limited (earlier known as Uni-Sankyo Ltd).

The Brand and Legacy

Bacillus coagulans is marketed in India under the brand name Sporlac and has been designated as strain ‘Bacillus coagulans SNZ 1969’ by Sanzyme Limited and Sanzyme Biologics.The strain Bacillus coagulans SNZ 1969 is deposited with Microbial TypeCulture Collection and Gene Bank, India (MTCC 5724P) and Belgian Coordinated Collections of Microorganism (BCCM™ILGM; LMG S−27484). US FDA has determined Bacillus coagulans SNZ 1969 strain as Generally Recognized As Safe (GRAS) based on scientific procedures (US FDA Notification GRN-597).

A Stronger Probiotic: Shielded, Resilient and Survives as the fittest!!

Bacillus coagulans SNZ 1969 shielded by natural capsules called spore. It can sustain hostile gastric and bile acids in human gut and remains stable in highly acidic (pH 2) environment. It is also resistant to high temperature i.e. up to 85°C for 30 min. From production to consumption, it does not show decrement in viability of cell. It sustains extreme manufacturing processes like fermentation, freezing, thawing,drying, and rehydration, making it the ideal probiotic for food applications. The safety and reliability of Bacillus coagulans SNZ 1969 is established not only by scientific studies but also by its unprecedented history of use for 46 years. Bacillus coagulans SNZ 1969 has also been studied for benefits in gut health, oral health and vaginal health.

 

 

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Introduction to Sanzyme’s Bacillus clausii SNZ 1971

Role of Bacillus clausii in gut dysbiosis

Normal microbial flora in the gut (called as gut microbiome) is considered as part of a defence system of gut. Our gut is exposed to unhealthy foods, allergens, antibiotics, and microbial and other toxins which causes adverse deviation of microbiome composition (known as gut dysbiosis). Probiotics bacteria may modulate and cross-talk with gut barrier and helps in replenishing gut microbiome. Bacillus clausii represents one of the most studied probiotics in this context. It also possess properties like resistance to commonly used antibiotics and production of antimicrobial substances against some pathogenic bacteria.

Why Bacillus clausii SNZ 1971

Sanzyme’s Bacillus clausii SNZ 1971 is a spore-forming bacterium that lives in the soil.Bacillus clausii SNZ 1971 is able to survive passage through the hostile environment like gastric and bile acid and germinate in the gut. Hence, though it is not the part of normal resident intestinal flora, it has the ability to colonize the intestine even in presence of antibiotics. By this way it helps in replenishing microbial flora and corrects dysbiosis.

Bacillus clausii SNZ 1971 received self-affirmed GRAS (generally recognized as safe) status and it is intended for use as a food ingredient for consumers in the following food categories: bakery (biscuits, pastries, cookies, brownies, crackers), cereal bars, dairy products (yogurt,cottage cheese, hard cheeses, and milk drinks and substitute products) and vegetable and fruit juices. Bacillus clausii SNZ 1971 has also been studied for its safety and its benefit in gut health.

 

 

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Sanzyme Biologics facility receives FAMI- QS certification

Sanzyme Biologics has received FAMI-QS certificate for implementing and maintaining a feed management system including good manufacturing practices in line with the FAMI-QS code.

FAMI-QS covers all feed ingredients and additives intended for animals as per European Regulation on feed hygiene, which Sanzyme Biologics has implemented and followed at their plant situated at Genome Valley in Hyderabad.

The company has worked for a number of years with some of the most established players in the animal feed industry to supply probiotics for their animal feed requirement supplying both, the companies’ own strains and formulations, as well as acting as a contract manufacturer for their strains. The FAMI-QS certification reaffirms the excellence for feed safety procedure at their world-class probiotic production facility.

Sanzyme Biologics is a specialized probiotic producer producing more than 30+ strains for its own products and for clients abroad. The company has a strong portfolio of sales in aquaculture with more than 25% market share in the Indian shrimp aquaculture markets. In addition to its own strains (including various Bacillus species, and yeasts), the company also acts as a CMO and CRO for companies looking to develop and produce their own probiotic strain to meet market needs.

FAMI-QS link is available here (Sanzyme Biologics (P) Limited FAM-1224): View Certification